Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Nasdaq, S&P 500 decline with tech; investors assess softer jobs data
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Leerink Partners Reiterates Market perform After Foundation Medicine (FMI) Reports Weak 2016 Guidance
February 24, 2016 9:35 AM ESTLeerink Partners reiterated a Market Perform rating on Foundation Medicine (NASDAQ: FMI), and cut the price target to $15.00 (from $27.00), following the company's 4Q earnings report. FMI reported 4Q revenue of $26.1M, above the Street's $25.1M estimate. 2016 revenue guidance of $110M-$120M was ~10%/6% below consensus at... More
Foundation Medicine (FMI) Tops Q4 EPS by 12c, Offers FY Guidance
February 23, 2016 4:05 PM ESTFoundation Medicine (NASDAQ: FMI) reported Q4 EPS of ($0.55), $0.12 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $26.1 million versus the consensus estimate of $25.76 million.
GUIDANCE:
Foundation Medicine sees Q1 2016 revenue of $110-120 million, versus the consensus of... More
